BioNTech SE ADR (BNTX) News

BioNTech SE ADR (BNTX): $156.53

-5.13 (-3.17%)

POWR Rating

Component Grades













Add BNTX to Watchlist
Sign Up

Industry: Biotech


of 462

in industry

Filter BNTX News Items

BNTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BNTX News Highlights

  • For BNTX, its 30 day story count is now at 95.
  • Over the past 29 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
  • The most mentioned tickers in articles about BNTX are SE, MRNA and PFE.

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

BioNTech down 9% following Israeli fourth COVID jab study on Omicron

Shares of BioNTech (BNTX -7.8%) have fallen this morning following results from an Israeli study showing that a fourth COVID-19 shot is less effective against the Omicron variant than prior strains. "We see an increase in antibodies, higher than after the third dose," said lead researcher Gili Regev-Yochay. "However, we see...

Seeking Alpha | January 18, 2022

This New Study Suggests Pfizer, BioNTech Are Losing The Omicron Battle

A fourth dose of Pfizer and BioNTech''s Covid shot is only partly effective against omicron, according to a new test. The vaccine stocks fell.

Investor''s Business Daily | January 18, 2022

Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling Today

Shares of vaccine makers, including Moderna Inc Full story available on

Benzinga | January 18, 2022

The Right Bet On BioNTech SE

No summary available.

Seeking Alpha | January 18, 2022

Omicron: Why a fourth dose of coronavirus vaccines may not be 'absolutely necessary,' doctor says

Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.

Yahoo | January 18, 2022

Top Biotech Stocks for Q1 2022

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | January 18, 2022

Pendal Group Ltd Buys NXP Semiconductors NV, Ferguson PLC, Unilever PLC, Sells Philip Morris ...

Investment company Pendal Group Ltd (Current Portfolio) buys NXP Semiconductors NV, Ferguson PLC, Unilever PLC, Taiwan Semiconductor Manufacturing Co, BioNTech SE, sells Philip Morris International Inc, Progressive Corp, Exelon Corp, Atmos Energy Corp, Sempra Energy during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pendal Group Ltd.

Yahoo | January 18, 2022

UPDATE 1-EU watchdog urges vaccine developers not to focus only on Omicron

The European Union drugs regulator said pharmaceuticals companies should work on more than one upgraded COVID-19 shot, not only tailored to the fast-emerging Omicron variant but also versions that address a combination of variants. "What we are hearing from other regulatory agencies also is that it is important not to exclude any options," the European Medicines Agency's head of vaccines strategy, Marco Cavaleri, told a media briefing on Tuesday. Vaccine makers working on a redesign of their established shots to address Omicron, which is crowding out the Delta variant in many regions of the world, include BioNTech-Pfizer , Moderna and the alliance between AstraZeneca and Oxford University.

Yahoo | January 18, 2022

Preliminary Israeli study shows fourth COVID booster doesn’t stop omicron infections

A fourth vaccine boost lifted antibodies, but omicron infections persisted, according to an unpublished study at an Israeli hospital

Yahoo | January 18, 2022

NVAX Stock Alert: Why Is Novavax Plunging Today?

With the vaccine mandate failing to pass, companies like Novavax face an uncertain future.

Samuel O'Brient on InvestorPlace | January 14, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6505 seconds.